Phase 3 Trials Positive for Erenumab in Migraine Prevention Phase 3 Trials Positive for Erenumab in Migraine Prevention

Both STRIVE and ARISE phase 3 trials met their primary outcomes, showing greater reductions in monthly migraine days for patients with episodic migraine treated with erenumab vs those receiving placebo.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news